Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease

Invokana sales may be muted, but the diabetes drug is set to get some love after its maker J&J unveiled data at the American Diabetes Association meeting on Tuesday suggesting the medicine can confer a cardiovascular benefit in patients who do not have preexisting CV disease.